DNA, siRNA, DNA & siRNA
Adherent cell lines grown in presence of serum
|Number of transfections|
1.5 ml of jetPRIME® transfection reagent is sufficient to perform up to 1500 transfections in 24-well plates or 375 transfections in 6-well plates
5°C ± 3°C, stable for at least one year when stored appropriately
jetPRIME® is a powerful and versatile DNA and siRNA transfection reagent for day-to-day experiments that leads to efficient and reliable scientific results. jetPRIME® ensures high DNA transfection efficiency and excellent gene silencing in a variety of adherent cells. jetPRIME ® is also ideal for DNA/siRNA co-transfection or co-delivery of several plasmids. Furthermore, our jetPRIME® reagent is very gentle on cells since it requires low amounts of reagent and nucleic acid during transfection.
|Reference Number||Amount of reagent||Amount of buffer|
|114-01||0.1 ml||5 ml|
|114-07||0.75 ml||60 ml|
|114-15||1.5 ml||2 x 60 ml|
|114-75||5 x 1.5 ml||10 x 60 ml|
Superior transfection efficiency
jetPRIME® is a powerful transfection reagent for day-to-day experiments. It leads to unusually high percentage of transfected adherent cell lines of various origins as well as primary cells.
Superior transfection efficiencies ranging between 70 and 90% were obtained with jetPRIME® reagent versus the top competitor’s reagent for several commonly used cell lines (Fig.1 & Fig.2).
Fig. 1: Comparative transfection efficiency of jetPRIME versus its main competitor. Transfection efficiency was assessed by FACS analysis in various cell lines 24 h after transfection in 24-well plates. Conditions were used according to the manufacturer’s recommendation for both Lipofectamine® 2000 and for jetPRIME®.
Fig. 2: Comparative transfection efficiency of jetPRIME® versus Lipofectamine® 3000. Transfection efficiency was assessed by FACS analysis in various cell lines 24 h after transfection in 96-well plates or 24-well plates. Conditions were used according to the manufacturer’s recommendation for lipofectamine® 3000 and for jetPRIME®.
Cost-effective: less DNA and less reagent
jetPRIME® is a powerful in vitro transfection reagent that requires a small amount of reagent and plasmid DNA, making its use very cost-effective (Table 1).
Table 1: Recommended conditions to use. Amounts of DNA and reagent (jetPRIME® and competitors) per well in 6-well plate for transfection according to manufacturers’ recommendations.
In addition to reducing costs, using less DNA also minimizes adverse cytotoxic effects triggered by transfection. Hence, jetPRIME® is the reagent of choice for high transfection efficiency with excellent cell viability.
Better cell viability
jetPRIME® is extremely gentle on cells during transfection leading to increased cell viability and improved transfection results. Cells transfected with jetPRIME® are healthy, while major cytotoxicity is observed with competitors (Fig.3).
Fig. 3: Cell viability 24h after transfection. Phase contrast microscopy of HeLa cells 24 h after transfections performed according to the manufacturer’s recommendations for each reagent.
Easy to use protocol
jetPRIME® is an easy-to-use transfection reagent (Fig.4):
- Fast and easy to scale up and down
- Compatible with serum and antibiotics
Fig. 4: jetPRIME® protocol. Convenient protocol for DNA, siRNA and co-transfection of DNA and siRNA.
Take a look at our Expert Tips to ace DNA transfection in our blog section.
jetPRIME® leads to remarkably high percentages of transfected adherent cell lines of various origin, as well as primary cells (Table 1).
Table 1: Transfection efficiency of various cell types using jetPRIME®. The percentage of GFP-positive cells was determined by FACS analysis 24 h after transfection.
Plasmids are small circular DNA molecules that are commonly found in bacteria. Plasmids exist and replicate separately from chromosomal DNA and in bacteria they often carry genes that are beneficial for bacterial survival. Plasmids can be deliberately introduced into desired cells and utilized to overexpress a gene of interest in a specific cell line. This procedure is called DNA transfection and is a commonly used method for studying gene function or protein of interest.
The use of the CRISPR/Cas9 system in mammalian cells has recently emerged as a very convenient way to modify the cell genome at a specific locus. It involves transient transfection into mammalian cells of either (a) one or several plasmids coding for Cas9, the specific gRNA and eventually the sequence to be inserted, or (b) a mix of one or two plasmids and an RNA molecule (the gRNA).
Available application note: CRISPR/Cas9-mediated gene disruption using jetPRIME®.
jetPRIME® leads to over 90% knockdown of endogenous gene expression in a variety of cell lines. For example, jetPRIME®-mediated transfection of HeLa cells with 10 nM siRNA duplexes targeting endogenous lamin A/C in HeLa cells drastically reduces lamin A/C gene expression to barely detectable level (Fig. 1).
Fig. 1: Endogenous lamin A/C silencing using jetPRIME®. HeLa cells were transfected with 10 nM of 21-mer lamin A/C siRNA. After 48 h, lamin A/C silencing was assessed by immunofluorescence microscopy using an antibody against lamin A/C .
Co-transfection of different nucleic acids
jetPRIME® is well suited for DNA and siRNA/ miRNA co-transfection experiments or co-delivery of several DNA plasmids.
We performed DNA and siRNA delivery with jetPRIME® and observed highly efficient gene silencing in a variety of cell lines with very low toxicity. Over 90% silencing is achieved in adherent cells, using 10 nM siRNA (Fig. 2).
Fig. 2: Exogenous luciferase silencing in several cell lines after DNA & siRNA cotransfection using jetPRIME®. Experiments were performed with 400 ng p4CMV-Luc and 10 nM of luciferase siRNA per well in 6-well plates.
Every batch of jetPRIME® reagent is tested in-house by DNA transfection of HeLa cells with a GFP-expressing plasmid and each vial of reagent is provided with Certificate of Analysis.
Thank you PolyPlus for developing this reagent for researchers.
In order to download a product protocol or a certificate of analysis, please create an account on Polyplus-transfection® Portal.
Why would you need to create an account?
In this personal area you will have access to:
- Product Protocols
- Certificates of Analysis
- Exclusive webinars/articles
- And surprise features!
Related blog posts
|Cell Line||in vitro|
|Delivered Molecule||Reagent||Results & Citations|
Shiloach, T. et al. (2014)
PLoS ONE 9, e101075
tLivin displays flexibility by promoting alternative cell death mechanisms
Gong Y. et al. (2019)
Pharmacol Res 148, 104460
Neohesperidin prevents colorectal tumorigenesis by altering the gut microbiota
Tomic, Goran, Morrissey, Edward, Kozar, Sarah, Ben-Moshe, Shani, Hoyle, Alice, Azzarelli, Roberta, Kemp, Richard, Chilamakuri, Chandra Sekhar Reddy, Itzkovitz, Shalev, Philpott, Anna, Winton, Douglas. et al. (2018)
Cell Stem Cell ,
Phospho-regulation of Atoh1 is required for plasticity of secretory progenitors and tissue regeneration
|Mouse primary fibroblasts||in vitro||DNA||jetPRIME|
Neueder, A. et al. (2014)
J Biol Chem 289, 19894-906
Novel isoforms of heat shock transcription factor 1, HSF1gammaalpha and HSF1gammabeta, regulate chaperone protein gene transcription
Li Y. et al. (2020)
Vet Microbiol 241, 108563
Porcine reproductive and respiratory syndrome virus infection promotes C1QBP secretion to enhance inflammatory responses
Calvayrac, O. et al. (2018)
J Pathol ,
Cytoplasmic p27(Kip1) promotes tumorigenesis via suppression of RhoB activity
Verma, S. et al. (2014)
PLoS Pathog 10, e1004268
Inhibition of the TRAIL death receptor by CMV reveals its importance in NK cell-mediated antiviral defense
Pei YF. et al. (2019)
Skelet Muscle 9, 28
Two functional variants at 6p21. 1 were associated with lean mass
Li, M. et al. (2018)
Biochem Biophys Res Commun 504, 238-244
Foot-and-mouth disease virus non-structural protein 2B negatively regulates the RLR-mediated IFN-beta induction
Ruvolo, P. P. et al. (2014)
Biochim Biophys Acta 1843, 1969-77
The protein phosphatase 2A regulatory subunit B55alpha is a modulator of signaling and microRNA expression in acute myeloid leukemia cells